The beneficial effects of systemic immunotherapies and targeted therapies in patients with metastatic disease have led to the pursuit of anti-cytotoxic-T-lymphocyte-associated antigen-4 (CTLA-4), anti-programmed cell death-1 (PD-1) monoclonal antibodies, and BRAF/MEK inhibitors in the adjuvant setting, where these agents have become the standard of care for treating stage III melanoma patients post-surgery, resulting in significant improvements in recurrence-free survival (RFS) [13,14,15]. This evidence concerns the gene PDCD1 and metastatic neoplasm.